体外循环相关血小板功能障碍与心脏手术不良结局的关联
本研究纳入3010例心脏手术患者,评估体外循环复温末期胶原激活后血小板功能障碍与复合不良结局的关联。复合结局发生率为8%(251/3010),风险调整后血小板功能障碍每增加1%,复合结局风险约增加1%(OR 1.012;95%CI 1.006-1.018),提示其具有预后价值。
要点
- 体外循环复温末期血小板功能障碍与复合不良结局独立相关(p < 0.001)。
- 血小板功能障碍每增加1%,复合结局风险约增加1%(OR 1.012;95%CI 1.006-1.018)。
- 该指标或可作为心脏手术止血激活的临床监测工具。
核心结论
- 体外循环相关血小板功能障碍具有预后价值,可能作为止血激活的临床测量指标。
研究设计与样本
- 本研究为探索性研究,纳入3010例心脏手术患者。
- 在体外循环复温末期,用床旁检测法以胶原激活后无功能血小板比例计算血小板功能障碍。
- 采用逻辑回归和多变量分析评估血小板功能障碍与复合结局的关联。
主要发现
- 复合结局(院内死亡、心肌梗死、卒中、深静脉血栓或肺栓塞、急性肾损伤)发生于251/3010例患者(8%)。
- 无结局者血小板功能障碍中位数(IQR[范围])为14%(8-28%[1-99%]),有结局者为19%(11-45%[2-98%]),p < 0.001。
- 风险调整后,血小板功能障碍与复合结局独立相关(p < 0.001),每增加1%复合结局风险约增加1%(OR 1.012;95%CI 1.006-1.018)。
关键数值与推荐
- 血小板功能障碍定义为胶原激活后无功能血小板比例。
- 复合结局包括院内死亡、心肌梗死、卒中、深静脉血栓或肺栓塞、急性肾损伤(肌酐升高大于两倍)。
临床怎么用
- 心脏手术中可考虑用床旁血小板功能检测评估体外循环相关止血激活。
- 复温末期血小板功能障碍程度或有助于术后不良结局的风险分层。
局限性
- 本研究为探索性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Haemostatic activation during cardiopulmonary bypass is associated with prothrombotic complications. Although it is not possible to detect and quantify haemostatic activation directly, platelet dysfunction, as measured with point-of-care-assays, may be a useful surrogate. In this study, we assessed the association between cardiopulmonary bypass-associated platelet dysfunction and adverse outcomes in 3010 cardiac surgical patients. Platelet dysfunction, as measured near the end of the rewarming phase of cardiopulmonary bypass, was calculated as the proportion of non-functional platelets after activation with collagen. Logistic regression and multivariable analyses were applied to assess the relationship between platelet dysfunction and a composite of in-hospital death; myocardial infarction; stroke; deep vein thrombosis or pulmonary embolism; and acute kidney injury (greater than a two-fold increase in creatinine). The outcome occurred in 251 (8%) of 3010 patients. The median (IQR [range]) percentage platelet dysfunction was less for those without the outcome as compared with those with the outcome; 14% (8-28% [1-99%]) vs. 19% (11-45% [2-98%]), p < 0.001. After risk adjustment, platelet dysfunction was independently associated with the composite outcome (p < 0.001), such that for each 1% increase in platelet dysfunction there was an approximately 1% increase in the composite outcome (OR 1.012; 95%CI 1.006-1.018). This exploratory study suggests that cardiopulmonary bypass-associated platelet dysfunction has prognostic value and may be a useful clinical measure of haemostatic activation in cardiac surgery.
引用
- Ho LTS, Lenihan M, McVey MJ, et al. The association between platelet dysfunction and adverse outcomes in cardiac surgical patients. Anaesthesia. 2019. PMID: 30932171. doi:10.1111/anae.14631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。